A Multiple-center, Multiple-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Parallel Group Study to Investigate the Effect of RO4917838 on the QTc Interval in Healthy Subjects

Trial Profile

A Multiple-center, Multiple-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Parallel Group Study to Investigate the Effect of RO4917838 on the QTc Interval in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2015

At a glance

  • Drugs Bitopertin (Primary) ; Moxifloxacin
  • Indications Bacterial infections; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 11 Sep 2012 Results published in Clinical Therapeutics.
    • 12 Aug 2012 Primary endpoint 'noninferiority between bitopertin and placebo in QT-interval changes at steady state' has been met.
    • 08 Jun 2012 New source identified and integrated: ClinicalTrials.gov record NCT01613040.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top